Share price · RHHBY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RHHBY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 23 Jul 2026+4.3%
- 13 Jul 2026-2.7%
Nothing announced by RHHBY that day or the session before.
- 2 Jul 2026+5.4%
- 1 Jul 2026-2.0%
- 1 Jun 2026-4.2%
Nothing announced by RHHBY that day or the session before.
- 13 Mar 2026-3.5%
Nothing announced by RHHBY that day or the session before.
- 5 Mar 2026-6.3%
Nothing announced by RHHBY that day or the session before.
- 29 Jan 2026+4.8%
Nothing announced by RHHBY that day or the session before.
- 18 Nov 2025+9.6%
- 10 Nov 2025+4.5%
Nothing announced by RHHBY that day or the session before.
Share of unusual movement by asset
For each asset, the share of RHHBY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(68 total)
| Target & Modality | |||
|---|---|---|---|
Alectinib(Alecensa) | Approved | ALKSmall molecule | Non-Small Cell Lung Cancer |
| Approved | PD-L1Monoclonal antibody | Non-Small Cell Lung CancerHepatocellular CarcinomaColorectal CancerBladder CancerSmall Cell Lung CancerMelanoma | |
Baxdrostat(Baxfendy) | Approved | Aldosterone synthase (CYP11B2)Small molecule | HypertensionHeart FailureChronic Kidney Disease |
| Approved | VEGF-A · Vascular Endothelial Growth Factor InhibitorMonoclonal antibody | Non-Small Cell Lung CancerOvarian CancerCervical CancerHepatocellular CarcinomaColorectal CancerRenal Cell CarcinomaGlioblastoma Metastatic Colorectal Cancer, Recurrent Glioblastoma | |
| Approved | MEK1/2Small molecule | Melanoma | |
| Approved | ROS1/NTRKSmall molecule | Non-Small Cell Lung Cancer | |
| Approved | Angiopoietin-2 / VEGF-AMultispecific antibody | Age-Related Macular DegenerationDiabetic Macular Edema Wet Age-Related Macular Degeneration | |
Inavolisib(Itovebi) | Approved | PI3K-alphaSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
| Approved | CD20Monoclonal antibody | Follicular LymphomaPrimary Membranous NephropathyLupus NephritisNon-Hodgkin LymphomaChronic Lymphocytic Leukemia | |
| Approved | CD20Monoclonal antibody | Multiple Sclerosis | |
| Approved | CD20Monoclonal antibody | Multiple Sclerosis | |
Omalizumab(Xolair) | Approved | IgE (immunoglobulin E) · IgEMonoclonal antibody | AsthmaChronic Spontaneous Urticaria |
| Approved | Type I interferon receptor | Chronic Hepatitis B | |
| Approved | HER2/neu Receptor AntagonistMonoclonal antibody | Breast Cancer HER2-Positive Breast Cancer | |
| Approved | PyridoneSmall molecule | Idiopathic Pulmonary Fibrosis |
Discontinued programmes (3)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(129 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (7)
November 2026 (3)
What to watch
What to watch
December 2026 (4)
2027 (38)
January 2027 (4)
What to watch
What to watch
What to watch
What to watch
February 2027 (3)
March 2027 (2)
April 2027 (2)
May 2027 (1)
What to watch
June 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (4)
What to watch
What to watch
What to watch
What to watch
September 2027 (1)
October 2027 (2)
November 2027 (2)
2028 (40)
January 2028 (2)
February 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
March 2028 (3)
April 2028 (2)
May 2028 (3)
June 2028 (4)
What to watch
What to watch
What to watch
What to watch
July 2028 (4)
What to watch
What to watch
What to watch
What to watch
August 2028 (2)
September 2028 (1)
October 2028 (2)
November 2028 (4)
What to watch
What to watch
What to watch
What to watch
December 2028 (4)
2029 (20)
January 2029 (1)
What to watch
February 2029 (3)
What to watch
What to watch
What to watch
March 2029 (1)
What to watch
April 2029 (2)
May 2029 (2)
What to watch
What to watch
June 2029 (3)
July 2029 (1)
What to watch
August 2029 (1)
What to watch
October 2029 (1)
What to watch
November 2029 (2)
What to watch
What to watch
2030 (7)
March 2030 (1)
What to watch
May 2030 (1)
What to watch
July 2030 (1)
What to watch
September 2030 (3)
What to watch
What to watch
What to watch
December 2030 (1)
What to watch
2031 (4)
January 2031 (1)
What to watch
March 2031 (2)
May 2031 (1)
What to watch
2032 (8)
January 2032 (3)
February 2032 (1)
What to watch
June 2032 (2)
July 2032 (1)
What to watch
September 2032 (1)
What to watch
2033 (5)
March 2033 (2)
What to watch
What to watch
May 2033 (1)
What to watch
July 2033 (1)
What to watch
Regulatory and conference events
(29)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
The 12 most recent of 24 past events are shown.
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-H1 | $37.2B | — | — | — | report ↗ |
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $35.9B | $7.7B | $15.2B | — | report ↗ |
| 2024-H1 | $33.6B | $8.3B | $9.8B | — | report ↗ |
| 2023-H1 | $32.7B | $7.6B | $8.4B | — | report ↗ |
| 2022-H1 | $34.2B | $7.3B | $7.1B | — | report ↗ |
| 2021-H1 | $33.8B | $7.8B | $8.7B | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $74.2B | $14.7B | — | — | report ↗ |
Roche reported revenue of $74,172.62M, up 8.0% YoY, and R&D spend of $14,710.09M, down 0.4% YoY. Cash position was not disclosed; core operating profit was CHF 21,833M, up 13% YoY at CER, and IFRS net income was CHF 13,799M, up 58% YoY at CER.
For 2026, Roche guided to mid single-digit Group sales growth and high single-digit core EPS growth at CER, with a further dividend increase planned. Pipeline highlights included US and EU approvals for subcutaneous Lunsumio, EU approval of Gazyva/Gazyvaro for lupus nephritis, positive phase III results for giredestrant, fenebrutinib, and other programs, and positive phase II data for CT-388; 10 key molecules advanced into phase III. Roche also completed its 89bio tender offer, obtained CE marks for diagnostic tests, and proposed a CHF 9.80 per share dividend, which would be the 39th consecutive increase.
Insider transactions
Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 67 reporting institutions held 5.6M shares ($251.8M, 0.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Aristotle Capital Management, LLC | 2,063,885 | $102.1M |
| 2 | Saratoga Research & Investment Management | 1,291,630 | $64.2M |
| 3 | Boston Common Asset Management, LLC | 322,354 | $16.0M |
| 4 | OLD NATIONAL BANCORP /IN/ | 257,854 | $12.6M |
| 5 | Altrius Capital Management Inc | 176,959 | $8.8M |
| 6 | HUNTINGTON NATIONAL BANK | 122,990 | $6.0M |
| 7 | RHUMBLINE ADVISERS | 98,944 | $4.9M |
| 8 | OPAL CAPITAL LLC | 89,483 | $4.4M |
| 9 | Sterling Capital Management LLC | 62,962 | $3.1M |
| 10 | KORNITZER CAPITAL MANAGEMENT INC /KS | 61,873 | $3.0M |
| 11 | Diversified Trust Co | 59,375 | $2.9M |
| 12 | YOUSIF CAPITAL MANAGEMENT, LLC | 52,832 | $2.6M |
| 13 | Patrick Mauro Investment Advisor, INC. | 45,578 | $2.3M |
| 14 | Wallington Asset Management, LLC | 40,264 | $2.0M |
| 15 | Associated Banc-Corp | 33,295 | $1.6M |